Objective The role of neutrophils in driving pathogenic B cell responses in SLE is not fully understood. In this study, we explored the link between immune complex (IC)–driven neutrophil activation, ...

Conclusions: In conclusion, CD38 expression emerges as a key prognostic marker in CLL, reinforcing the need to integrate clinical, biological, phenotypic, and molecular factors into treatment decision ...

Johnson & Johnson has generated evidence that the pace of oncology innovation is overwhelming physicians. A recent survey commissioned by the company found oncologists are struggling to keep up ...

Ask the publishers to restore access to 500,000+ books. An icon used to represent a menu that can be toggled by interacting with this icon. A line drawing of the Internet Archive headquarters building ...

Daratumumab (Darzalex) is a human immunoglobulin G1 k (IgG1k) monoclonal antibody designed to bind to CD38 proteins in multiple myeloma cells and activate immune cells, such as natural killer cells ...

One of the most-favored quadruplet regimens consists of the anti-CD38 monoclonal antibody daratumumab (Darzalex) combined with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd).

ISB 2001 is an investigational trispecific antibody therapeutic that targets BCMA and CD38 on myeloma cells and CD3 on T cells. It is currently being evaluated in a phase 1 dose-expansion study. “A ...

Both Darzalex Faspro and Sarclisa target the CD38 protein on the surface of multiple myeloma cells. The FDA also approved Abecma (idecabtagene vicleucel), a second chimeric antigen receptor T cell ...

The designation is specifically for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy, including a proteasome ...

This indication is for patients with RRMM who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The ...